文献速递血栓与止血造血干细胞移植与细胞治疗

儿童及年轻成人造血干细胞移植相关血栓性微血管病的依库珠单抗精准给药算法

Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT.
PubMed 文献 · Blood Adv · 2022-01-01

该研究在19例出血和38例非出血的移植相关血栓性微血管病(TA-TMA)患者中分析依库珠单抗的药代动力学/药效学,发现出血患者首剂后清除率更高(83.8 vs 61.3 mL/h每70 kg,P=0.07),现有非典型溶血性尿毒症综合征给药方案达标概率低于15%,并据此提出精准给药算法。

要点

  • 出血患者首剂后依库珠单抗清除率高于非出血患者(83.8 vs 61.3 mL/h每70 kg,P=0.07)。
  • 非出血患者清除率随时间下降,出血患者高清除率持续存在。
  • 现行非典型溶血性尿毒症综合征给药方案在非出血患者中达到目标浓度>100 μg/mL的概率低于15%。

核心结论

  • 数据明确显示,对有明显出血的TA-TMA患者需要个体化给药,并需持续调整剂量以优化结局。
  • 所建模型将纳入临床决策指南,用于精准给药以改善儿童及年轻成人TA-TMA患者的结局。

研究设计与样本

  • 在19例出血和38例非出血的TA-TMA患者(年龄0.5至29.9岁)中分析依库珠单抗的药代动力学/药效学。
  • 建立出血与非出血患者的独立模型,并提出精准给药算法。

主要发现

  • 补体激活生物标志物sC5b-9和体重被确定为依库珠单抗清除率的显著决定因素,与出血无关。
  • 出血患者首剂后依库珠单抗清除率为83.8 mL/h每70 kg,非出血患者为61.3 mL/h每70 kg(P=0.07)。
  • 出血患者在高清除率在治疗剂量期间持续存在,而非出血患者清除率随时间下降。
  • sC5b-9水平在首剂前最高,随时间下降,与出血并发症无关。
  • 蒙特卡洛模拟分析显示,现行推荐用于非典型溶血性尿毒症综合征的给药方案在非出血患者中达到目标浓度>100 μg/mL的概率低于15%。

关键数值与推荐

  • 依库珠单抗目标浓度为>100 μg/mL。
  • 出血患者首剂后清除率83.8 mL/h每70 kg vs 非出血患者61.3 mL/h每70 kg(P=0.07)。
  • 现行非典型溶血性尿毒症综合征给药方案在非出血患者中达标概率低于15%。
  • 强化负荷方案达到80%目标达标率。

临床怎么用

  • 作者认为,对有明显出血的TA-TMA患者需要个体化给药,并需持续调整剂量以优化结局。
  • 所建模型将纳入临床决策指南用于精准给药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal posttransplant complication of hematopoietic stem cell transplantation. We recently reported that survival for TA-TMA has been improved by early intervention with eculizumab, a complement C5 inhibitor, guided by pharmacokinetic/pharmacodynamic (PK/PD) model-informed precision dosing. However, patients with gastrointestinal bleeding showed poor survival, even when treated with more frequent doses. Our objective was to develop separate models in bleeding and nonbleeding patients with TA-TMA and to propose precision dosing algorithms. Eculizumab PK/PD was analyzed in 19 bleeding and 38 nonbleeding patients (0.5-29.9 years of age). A complement activation biomarker (sC5b-9) and body weight were identified as significant determinants of eculizumab clearance regardless of bleeding. Eculizumab clearance after the first dose was higher in bleeding than in nonbleeding patients (83.8 vs 61.3 mL/h per 70 kg; P = .07). The high clearance was maintained over treatment doses in bleeding patients, whereas nonbleeding patients showed a time-dependent decrease in clearance. sC5b-9 levels were highest before the first dose and decreased over time, regardless of bleeding complications. A Monte Carlo Simulation analysis showed that the current dosing protocols recommended for atypical hemolytic uremic syndrome had <15% probability of attaining the target concentration of >100 μg/mL eculizumab in nonbleeding patients. We identified an intensified loading protocol to reach 80% target attainment. Our data clearly showed the need for individualized dosing for patients with significant bleeding and for ongoing dose adjustments to optimize outcomes. The developed models will be incorporated into a clinical decision guideline for precision dosing to improve outcomes in children and young adults with TA-TMA.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mizuno K, Dandoy CE, Teusink-Cross A, et al. Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Adv. 2022. PMID: 35008105. doi:10.1182/bloodadvances.2021006523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。